Head-to-head clinical analysis: CLINIMIX E 4 25 10 SULFITE FREE W ELECT IN DEXTROSE 10 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 10 IN PLASTIC CONTAINER.
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER vs TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides a source of amino acids and dextrose for parenteral nutrition; amino acids support protein synthesis, dextrose provides calories. Electrolytes maintain fluid and electrolyte balance.
Travasol 2.75% with electrolytes in dextrose 10% is a parenteral nutrition solution. Amino acids provide substrate for protein synthesis, dextrose supplies calories, and electrolytes maintain acid-base balance and osmotic equilibrium.
Intravenous infusion. Dose is based on nutritional requirements and metabolic tolerance. Typical adult dose: 1-2 L per day (providing 4.25% amino acids and 10% dextrose) at a rate not exceeding 4 mg/kg/min of dextrose. Administer via central line or peripheral vein if osmolarity permits.
Intravenous infusion. Dosage depends on caloric and nitrogen requirements, generally 1-3 L per day in adults providing 4.25 g amino acids and 100 g dextrose per liter.
None Documented
None Documented
Amino acids: 0.5-1 hour (rapid clearance from plasma). Dextrose: effectively infinite as continuous infusion maintains steady state. Electrolytes: dependent on renal function and tubular handling.
Not applicable as a single entity; components have variable half-lives. Dextrose has elimination half-life of ~2-4 hours; amino acids have variable half-lives based on individual metabolic rates.
Amino acids: primarily deaminated in liver, urea excreted renally. Dextrose: metabolized to CO2 and water, with excess excreted renally as glucose. Electrolytes: renal excretion. No significant biliary/fecal elimination for components.
Renal (primarily as unchanged drug and metabolites). Biliary/fecal excretion is negligible (<5%).
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution